No Data
BIOCYTOGEN-B: 2024 Interim Report
Baostar Technologies Limited (02315.HK) received a shareholding increase of 0.7 million shares from Veken Trading (Hong Kong) Limited.
According to the latest equity disclosure information from the Hong Kong Stock Exchange, on September 11, 2024, Vico (Hong Kong) Economic and Trade Limited purchased 0.7 million shares of Baoshitubo-B (02315.HK) on the exchange at an average price of HK $5.85 per share, with a total investment of approximately HK $4.095 million. After the increase, the latest holding of Vico (Hong Kong) Economic and Trade Limited is 7.10258 million shares, and the shareholding ratio has increased from 5.78% to 6.41%.
Picoocart-B (2315.HK): Continuous revenue growth, significant narrowing of losses, positive operation cash flow, successful landing imminent.
In the past two or three years, innovation, going global, and profitability have become a consensus among entrepreneurs and investors in the domestic biomedical industry after the roller coaster-like changes. From the perspective of the capital markets, the performance of the innovative drug sector in the Hong Kong stock market in recent years has been disappointing, and the market's valuation attitude towards this sector has changed from overvaluation bubble to irrational undervaluation. With the continuous adjustment of sector valuation, it is currently at a historical low, providing a good opportunity for value-seeking investors. At this point in time, overseas innovative drug research and development is still thriving, and the domestic market is also gradually receiving support from the latest policies and market demand.
BIOCYTOGEN-B: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024
Biosino Biotechnology and Science Inc. (02315.HK) plans to hold a board of directors meeting on August 28 to approve its mid-term performance.
Baioo Science and Technology-B (02315.HK) announced on August 16 that the board of directors meeting will be held on Wednesday, August 28, 2024, to consider and approve the mid-term performance of the company and its subsidiaries for the six months ending June 30, 2024 (including but not limited to) and to consider the payment of mid-term dividends (if any).
Company profit warning: Biosyentech (02315) is expected to have a maximum mid-term loss of 5.47 million RMB, a decrease in losses of up to 76.4% year-on-year.
As of June 30, 2024, the six-month period, Baiostar (02315) announced an expected loss of approximately 4.47 million to 5.47 million yuan (RMB), a decrease of approximately 1.351 million to 1.451 million yuan compared to the same period of the previous year, a year-on-year decrease of approximately 71.2% to 76.4%. The Group's estimated revenue for the first half of the year is expected to be approximately 0.406 billion to 0.416 billion yuan, an increase of approximately 7.87 million to 8.87 million yuan compared to the same period of the previous year, a year-on-year increase of approximately 24.1% to 27.1%. The Group's estimated R&D expenses in the first half of the year.
No Data
No Data
meowmeow66 : I dont think moomoo can order this IPO. you can ask customer service to double check.